Contemporary Amperex Technology's net profit in Q3 increased by 6% year-on-year. Executives stated that production capacity utilization in Q4 is "more full", while the board secretary responded to the factory fire incident. | Interpretations

Contemporary Amperex Technology's Q3 net profit was 13.136 billion yuan, with a 6% increase compared to the previous quarter. During the performance interpretation meeting held on the night of the performance release, Nandu Times executives expressed their outlook on Q4 orders in this way; Executives responded to investor concerns such as the expected resumption of lithium carbonate production in Yichun and factory fires during the Q3 performance interpretation meeting.

cls.cnOct 18 12:07 ET

Stable growth in profits! Contemporary Amperex Technology's net income in Q3 increased by 25.97% year-on-year | Financial Report Insights

More news, continuously updated.

wallstreetcnOct 18 06:52 ET

It is expected that relevant national authorities will establish a low-altitude economic regulatory bureau.

①The establishment decision has been approved, and the new bureau is currently in preparation; ② The low-altitude economy set up a dedicated bureau, which can better coordinate resources at all levels to promote industrial development.

cls.cnOct 18 01:13 ET

Up nearly 10%! Taiwan Semiconductor's performance is better than expected across the board. AI may still be one of the clearest main themes in the market.

①TSMC's stock in the US surged nearly 10%, closing at a record high of $205 per share. TSMC previously announced its third-quarter financial report, with all indicators stronger than expected, and also raised its performance guidance. ②Guosheng Securities' research report pointed out that AI computing power is still one of the clearest main themes in the market in the present and even in the next two to three years, and the trend of industrial development has already taken shape.

cls.cnOct 17 19:47 ET

Slow progress in mergers and acquisitions raises doubts, cspc innovation pharmaceutical's earnings conference only addressed a few questions | Live coverage of the earnings conference

At the semi-annual earnings conference, CSPC Innovation Pharmaceutical only addressed a few issues. Due to the slow progress of the company's acquisition of CSPC Pharma's Baike Biotech, it has caused dissatisfaction among many investors. The company's secretary and CFO, Dai Long, stated that Enoxurumab injection, which was approved for listing in June, has been launched for sale.

cls.cnOct 15 09:38 ET

The central bank's new tool speeds up implementation! Beginning with middle letter, the repurchase frenzy is set off. Which Hong Kong stocks are expected to follow?

1. What impact will the central bank's accelerated implementation of the repurchase shareholding policy have on the market? 2. The trend of repurchasing starting with middle letter raises what signals?

cls.cnOct 15 03:44 ET